10Mon·

$HIMS (-0.44%) further increased, now the largest single position in the portfolio.

attachment

Despite strong growth of 50% Y/Y and profitability, the company is still valued low with a P/E ratio of approx. 3.


Well positioned in the younger generation, exciting product range with shameful products that one would rather buy online.

Perhaps the positioning in the lower middle price segment of its generics could be useful here. When it comes to sensitive issues such as hair loss or love life, people are more likely to steer clear of the cheapest product and opt for a good price-performance ratio.


The recent decline is probably due to the end of the emergency situation for weight loss injections. It seems to have been priced in for the time being.

And even if they are no longer allowed to sell their own syringes, they can still be intermediaries.


But I won't be taking in many more shares, otherwise the lump will get too big.


What do you think?

22.08
Hims & Hers logo
Bought x90 at €15.00
€1,350.00
11
23 Comments

profile image
Unfortunately 60% sold far too early, I am thinking of buying up again. My entry price is € 5.19 . However, I have not yet been able to bring myself to do so. I am still undecided whether I should wait for September.
4
profile image
@BamBamInvest With this additional purchase, I am now at a cost price of € 7.20.
Why wait for September? Because of the US interest rate decision?
I deliberately bought beforehand as I think the probability of a rate cut is higher than no cut... We will see.
1
profile image
@Money-Man Do you think we will have a soft landing after the interest rate cut?
profile image
@Money-Man I don't really know, I expect another small correction/ setback in September. Then $HIMS will not remain unscathed and the $NVDA figures next week will also be important. As I am already invested, I have no time pressure.
1
How did you become aware of the company so early on?
profile image
@dividend_hero_100 because I had been involved in the telemedicine sector during Corona. However, I had also bought steadily from EUR 10 into falling prices because growth continued to be strong until the turnaround came. Unfortunately, I sold a large part of the position too early because it was too big and I didn't have the nerve.
1
profile image
@LowTERror Difficult. Nobody can predict that. I actually prepared myself for the fact that there would be no soft landing and built up cash. But it looks to me a bit like it could work out after all. Market timing just doesn't work... so in.
If you don't invest in over-indebted companies, I think you can take a more relaxed approach.
4
profile image
A good share in my opinion:

+ EV / Sales (3.15)
+ Rule-of-40 Score TTM (58.54%)
+ Sales growth TTM (50.15%)
+ Debt ratio (0.03)

The gross margin TTM (74.20%) and the PEG TTM (1.95) also look good, but could be a little better ✌🏻
2
P/E ratio too high
1
profile image
@FYBSTRD What P/E ratio would be appropriate in your view?
@Money-Man The share is out of the question for me for this reason there is no target P/E ratio for me. Why Him & Hers with a P/E ratio of 80 when I can have a Microsoft or Alphabeth that are cheaper and have been delivering for years? Hims & Hers is everything but not cheap, imo
profile image
In my opinion, you can't / shouldn't put the P/E ratio on the golden scale for such high-growth stocks ✌🏻
2
@Anderle You're right about that. But where exactly is the moat? I really haven't looked into the UN much, but if I'm reading this right they sell prescription drugs online (probably with counseling), among other things. Why shouldn't a fat cat like CVS or Amazon do the same in the future? In my opinion, the P/E ratio is too high because there is no moat at the same time. Take a look at Oatly, which has grown without end, and today there is milk from every manufacturer. But as I said, I have not studied the UN in depth and what I have said is just my opinion. Hopefully I'm wrong and all those who have invested will soon have a tenfold increase in their portfolio, I hope so
1
profile image
@FYBSTRD The other providers are already doing this to some extent. However, the market for telemedicine is growing dramatically, especially in the next ten years due to the ageing society. There is enough room for several providers to grow. On the subject of moats: A moat can also simply be the brand itself (Coca Cola always comes to mind here as an example --> does Coca Cola have better cola than other providers? No! In a blind tasting on the street, 90 percent cannot identify Coca Cola from various colas, yet they are the leader in this segment because the bottle simply says "Coca Cola".
2
profile image
@FYBSTRD And on the subject of P/E ratios. You're right, but not really. The P/E ratio looks astronomically high (currently 220). But a company that has just reached break-even three quarters ago and is growing extremely fast cannot be valued with a P/E ratio. You now have EPS of around 7 cents for the last 4 quarters combined. In the next quarter alone, I expect earnings of around 8 cents per share. If that happens, the P/E ratio would suddenly be just 100, and we're only talking about a single quarter ... If this accelerates even further in the quarters thereafter, then good night
1
@Leipziger_Jung I'll keep my fingers crossed for you
profile image
@FYBSTRD Theoretically, the future P/E ratio is not really high with the same growth, regardless of whether it should be used for valuation or not. Of course it is now at around 80 and in 2026 we will be at 30-35, unless it turns out even better. But that is precisely the opportunity and the risk.
profile image
@BamBamInvest How do you arrive at a current P/E ratio of 80? It's currently over 200, or are you assuming that by the end of the year?
profile image
@Leipziger_Jung look at all the good financial sites or do the math, don't use getquin as a benchmark here. If you can open it:

https://at.marketscreener.com/kurs/aktie/HIMS-HERS-HEALTH-INC-109987976/finanzen/
View all 4 further answers
Join the conversation